$COAG

Hemab Therapeutics Holdings, Inc.

Hemab Therapeutics is a biotechnology company developing treatments for blood coagulation disorders. Its pipeline includes HMB-001, a bispecific antibody being developed for Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002, a monovalent antibody for von Willebrand disease. The company also works on earlier-stage drug candidates and is based in Cambridge, Massachusetts, with operations in the United States and Denmark.

No enriched coverage for $COAG in the last 7 days.

No SEC Form 4 filings for $COAG in the last 30 days.

See all $COAG insider activity →
Med

Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A

COAG sentiment & insider activity

Recent COAG coverage spans financial news, earnings and technology.

What's driving COAG

AlphAI scores every news story that mentions COAG with an AI model for sentiment and relevance, and aggregates insider trades from Hemab Therapeutics Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $COAG

Score

Hemab (COAG) Q3 2026 Earnings Call Transcript

Hemab (COAG) reported Q3 2026 progress, including Phase I trial initiation for HMB-003, Phase III trial start for sutacimig in Glanzmann thrombasthenia, and preclinical data for HMB-002. The company added Keli Walbert to its board and is building its commercial strategy. Sutacimig showed promising results in reducing bleeds, and HMB-003 aims to address heavy menstrual bleeding, a condition affecting millions of women.

What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call

Hemab Therapeutics (COAG) reported a Q3 net loss of $27.3 million, up from $17.1 million a year earlier. The company plans to present updated Phase 2b data for its Factor VII deficiency treatment and new data for its von Willebrand disease treatment in 2027. Preclinical data for its heavy menstrual bleeding candidate will also be presented in December. R&D expenses rose to $24.6 million, driven by clinical program advances.

$COAGMedAI 8/10Earnings

Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding, a condition affecting more than 23 million women in the U.S. alone A

$COAGLowAI 8/10

Hemab initiates phase 3 trial for rare bleeding disorder drug

Hemab Therapeutics (COAG) began a Phase 3 trial for sutacimig, a treatment for Glanzmann thrombasthenia, a rare bleeding disorder. The single-arm trial will enroll 75 participants, with the primary endpoint being the annualized treated bleed rate. The FDA recommended a randomized design, but Hemab proceeded with a single-arm trial due to feasibility concerns. Sutacimig has received Fast Track, Orphan Drug, and Breakthrough Therapy Designations from the FDA.

JPMorgan initiates Hemab Therapeutics stock with overweight rating

JPMorgan initiated coverage on Hemab Therapeutics (COAG) with an overweight rating and $70 price target, citing its pipeline for bleeding disorders. The stock is currently at $29.94, 46% below its 52-week high. Analysts project significant revenue potential for its lead assets, sutacimig and HMB-002, with combined revenue estimates of $4.6 billion by 2044. Other analysts have also raised price targets, reflecting positive sentiment.

$COAGMedAI 8/10

Rodman & Renshaw initiates Hemab stock with buy on therapy potential

Rodman & Renshaw initiated coverage on Hemab Therapeutics (NASDAQ:COAG) with a buy rating and $56.00 price target, citing potential of sutacimig for Glanzmann thrombasthenia. The company is also developing treatments for Von Willebrand disease. Hemab has a strong balance sheet with a current ratio of 35.85. Recent phase 2 data showed promising results, leading H.C. Wainwright to raise its price target to $60.

$COAGLowExec change· elected

Hemab Therapeutics Holdings, Inc. (COAG): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Direct

$COAGMedEarnings

Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Hemab Therapeutics Holdings, Inc. (COAG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hemab Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Cong

Biotech Stocks At 52-Week Highs - XNCR, COAG, MNPR, SOPH, ACRS

Biotech stocks hit 52-week highs on July 20, 2026, attributed to upcoming clinical catalysts. Xencor (XNCR) reached $20.26, up 7%, with Phase 2b XENITH-UC interim results expected by year-end 2026. Hemab (COAG) hit $52.15 after positive Phase 2 Sutacimig data. Monopar (MNPR) hit $115 on Phase 3 ALXN1840 Wilson disease results. SOPHiA (SOPH) rose above $6.50; Q1 revenue was $21.7M and 2026 guidance is $92M to $94M.

Related tickers